Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.

We report the use of the steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the management of patients with advanced, hormone resistant, prostatic cancer. Eighteen of 25 patients (72%) showed a subjective response, mainly in the form of pain relief and increased performan...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Davies, J. H., Dowsett, M., Jacobs, S., Coombes, R. C., Hedley, A., Shearer, R. J.
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 1992
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977910/
https://ncbi.nlm.nih.gov/pubmed/1637664
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍